Anne‐Christine Bay‐Jensen

Research interests

Publications

• Osteoarthritis endotype discovery via clustering of biochemical marker data

  Annals of the Rheumatic Diseases · 2022 · 10.1136/annrheumdis-2021-221763

• Dermal fibroblasts have different extracellular matrix profiles induced by TGF-β, PDGF and IL-6 in a model for skin fibrosis

  Scientific Reports · 2020 · 10.1038/s41598-020-74179-6

• Recent advances in understanding the phenotypes of osteoarthritis

  F1000Research · 2019 · 10.12688/f1000research.20575.1

• Osteoarthritis phenotypes and novel therapeutic targets

  Biochemical Pharmacology · 2019 · https://doi.org/10.1016/j.bcp.2019.02.037

• Molecular taxonomy of osteoarthritis for patient stratification, disease management and drug development: biochemical markers associated with emerging clinical phenotypes and molecular endotypes

  Current Opinion in Rheumatology · 2018 · 10.1097/bor.0000000000000567

• Osteoarthritis Year in Review 2016: biomarkers (biochemical markers)

  Osteoarthritis and Cartilage · 2017 · 10.1016/j.joca.2016.12.016

• The minor collagens in articular cartilage

  Protein & Cell · 2017 · https://doi.org/10.1007/s13238-017-0377-7

• Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix

  Osteoarthritis and Cartilage · 2017 · 10.1016/j.joca.2017.08.004

• Association between biomarkers of tissue inflammation and progression of osteoarthritis: evidence from the Rotterdam study cohort

  Arthritis Research & Therapy · 2016 · 10.1186/s13075-016-0976-3

• Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future

  Osteoarthritis and Cartilage · 2016 · https://doi.org/10.1016/j.joca.2016.07.017

• Novel insights into the function and dynamics of extracellular matrix in liver fibrosis

  American Journal of Physiology-Gastrointestinal and Liver Physiology · 2015 · https://doi.org/10.1152/ajpgi.00447.2014

• Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials

  Osteoarthritis and Cartilage · 2015 · 10.1016/j.joca.2014.12.019

• The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases

  BMC Musculoskeletal Disorders · 2014 · 10.1186/1471-2474-15-93

• Osteoarthritis – a case for personalized health care?

  Osteoarthritis and Cartilage · 2013 · 10.1016/j.joca.2013.10.018

• The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?

  Annals of the Rheumatic Diseases · 2013 · 10.1136/annrheumdis-2013-204111

• Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue Diseases Possibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure

  Assay and Drug Development Technologies · 2012 · https://doi.org/10.1089/adt.2012.474

• IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)

  Seminars in Arthritis and Rheumatism · 2012 · 10.1016/j.semarthrit.2012.01.004

• A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)

  Biomarkers · 2011 · 10.3109/1354750x.2011.620628

• Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—Increased serum CIIM in subjects with severe radiographic osteoarthritis

  Clinical Biochemistry · 2011 · 10.1016/j.clinbiochem.2011.01.001

• Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities

  Arthritis Research & Therapy · 2011 · 10.1186/ar3280

• Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?

  Clinical Biochemistry · 2010 · 10.1016/j.clinbiochem.2010.03.015

• Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

  Rheumatology International · 2009 · 10.1007/s00296-009-1183-1

• MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation – divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation

  Osteoarthritis and Cartilage · 2009 · 10.1016/j.joca.2009.11.005

• Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

  Biomarkers · 2009 · 10.1080/13547500902777608

• The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?☆

  Pharmacological Research · 2008 · 10.1016/j.phrs.2008.06.001

Current projects

No projects listed.